Veru (NASDAQ:VERU) Announces Earnings Results, Beats Expectations By $0.01 EPS

Veru (NASDAQ:VERU) posted its quarterly earnings data on Monday. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01, Zacks reports. Veru had a negative return on equity of 115.99% and a negative net margin of 376.38%.

Veru Stock Up 8.7 %

VERU traded up $0.06 during trading hours on Monday, hitting $0.79. The stock had a trading volume of 2,370,238 shares, compared to its average volume of 1,602,859. The stock has a market cap of $114.97 million, a PE ratio of -1.64 and a beta of -0.50. Veru has a 1 year low of $0.36 and a 1 year high of $1.92. The company’s fifty day simple moving average is $0.76 and its 200 day simple moving average is $0.82.

Analysts Set New Price Targets

Separately, Oppenheimer restated an “outperform” rating and set a $5.00 price target on shares of Veru in a research report on Tuesday, November 5th.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.